Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 7/20 | 0.39 |
| ▸ | CA1 | P00915 | 7/20 | 0.39 |
| ▸ | CA9 | Q16790 | 7/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.36 |
| ▸ | AGXT | P21549 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13888301 | 0.83 | CA12 (0.44) | HPGDNPC1RAB9ACA12CA1 | |
| SCHEMBL3824052 | 0.82 | CA12 (0.50) | HPGDNPC1RAB9ACA12CA1 | |
| SCHEMBL11580959 | 0.81 | NQO2 (0.50) | HPGDNPC1RAB9ACA12CA1 | |
| SCHEMBL293760 | 0.78 | CYP3A4 (0.46) | HPGDNPC1RAB9AALDH1A1TSHR | |
| SCHEMBL470906 | 0.75 | CA12 (0.57) | NPC1RAB9ACA12CA1CA9 | |
| SCHEMBL30541768 | 0.75 | CA12 (0.57) | NPC1RAB9ACA12CA1CA9 | |
| SCHEMBL4083623 | 0.75 | ALOX5 (0.59) | NPC1RAB9ACYP3A4MAPT | |
| SCHEMBL293052 | 0.75 | AGXT (0.41) | HPGDNPC1RAB9ACA12CA1 | |
| SCHEMBL20554924 | 0.75 | HPGD (0.43) | HPGDCA12CA1CA9CA2 | |
| SCHEMBL20530588 | 0.74 | MAOB (0.46) | HPGDCA12CA1CA9CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108368069-B | Oxazine compound, composition and cured product | DIC株式会社 | 2022-10-14 | — | — | CN | disclosed |
| US-10399312-B2 | Oxazine compound, composition and cured product | DIC CORPORATION (JP) | 2019-09-03 | — | — | US | disclosed |
| US-20180333941-A1 | OXAZINE COMPOUND, COMPOSITION AND CURED PRODUCT | DIC CORPORATION (JP) | 2018-11-22 | — | — | US | disclosed |
| EP-3401311-A1 | OXAZINE COMPOUND, COMPOSITION AND CURED PRODUCT | DIC Corporation (JP) | 2018-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180333941-A1 | OXAZINE COMPOUND, COMPOSITION AND CURED PRODUCT | KDM5A, PSMB5, CUL5 | HPGD 1322/4885NPC1 3956/4885RAB9A 4840/4885 |
| US-10399312-B2 | Oxazine compound, composition and cured product | KDM5A, PSMB5, CUL5 | HPGD 1322/4885NPC1 3956/4885RAB9A 4840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.